Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
Study Details
Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related Kaposi's sarcoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
- Determine whether the body distribution and plasma clearance of paclitaxel is affected by protease inhibitors (e.g., indinavir, ritonavir, saquinavir mesylate, or nelfinavir mesylate).
OUTLINE: Patients are stratified according to protease inhibitor treatment (yes vs no), prior paclitaxel (yes vs no), and prior doxorubicin or daunorubicin (yes vs no).
Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 2 weeks for at least 1 course in the absence of disease progression or unacceptable toxicity. Patients who previously received paclitaxel receive no more than 1 course during this study.
PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed Kaposi's sarcoma requiring chemotherapy and/or currently being treated with paclitaxel
-
Serologic diagnosis of HIV infection documented by a positive ELISA and confirmed with a Western Blot or other federally approved HIV diagnostic test
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
-
Absolute neutrophil count at least 1,000/mm ^3(with or without the use of colony-stimulating factors)
-
Platelet count at least 50,000/mm^3
Hepatic:
-
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
-
AST no greater than 2.5 times ULN
-
Alkaline phosphatase no greater than 2.5 times ULN
Renal:
-
Creatinine no greater than 1.5 mg/dL OR
-
Creatinine clearance greater than 60 mL/min
Neurologic:
-
No greater than grade 2 peripheral neuropathy
-
No neuropsychiatric history or altered mental status that would preclude study
Other:
-
Not pregnant or nursing
-
Fertile patients must use effective contraception
-
No other prior or concurrent malignancy except curatively treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
-
No sensitivity to E. coli-derived proteins
-
No active untreated infection
-
No new infectious complications requiring a change in antibiotics within the past 2 weeks
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
Endocrine therapy:
- Not specified
Radiotherapy:
-
At least 1 week since prior radiotherapy
-
No prior radiotherapy to marker lesions
-
No concurrent radiotherapy
Surgery:
- Not specified
Other:
-
At least 2 weeks since prior systemic treatment for Kaposi's sarcoma
-
At least 2 weeks since prior nonapproved FDA investigational agents except available Investigational New Drugs that are antiretroviral agents
-
Concurrent maintenance therapy for opportunistic infections allowed
-
Concurrent commercially available antiretroviral therapy allowed
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | United States | 35294-3300 |
Sponsors and Collaborators
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
- AIDS Associated Malignancies Clinical Trials Consortium
Investigators
- Study Chair: Jamie Hayden Von Roenn, MD, Robert H. Lurie Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000065583
- E1D95
- AMC-014